Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough, has announced a public offering of $100 million in common stock. The company has also granted underwriters a 30-day option to purchase an additional $15 million in shares. The offering is being managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor. The final terms will be detailed in a forthcoming prospectus supplement, and the offering is contingent on market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.